Back to Search
Start Over
Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
- Source :
- 50 Studies Every Urologist Should Know
- Publication Year :
- 2021
- Publisher :
- Oxford University Press, 2021.
-
Abstract
- This chapter summarizes the findings of the landmark CheckMate 025 trial for the new class of drugs of immune checkpoint blockade in advanced renal cell cancer. The trial randomized patients with metastatic renal cell carcinoma who had failed antiangiogenic therapy to systemic therapy with nivolumab versus everolimus and found improved overall survival and fewer treatment-related adverse events in the nivolumab arm.
Details
- Database :
- OpenAIRE
- Journal :
- 50 Studies Every Urologist Should Know
- Accession number :
- edsair.doi...........dae9c0ac4b83b822b7ea00c302b84032
- Full Text :
- https://doi.org/10.1093/med/9780190655341.003.0022